自体外周血造血干细胞移植治疗恶性血液病20例临床分析

目的观察自体外周血造血干细胞移植（APBSCT）治疗恶性血液病的初期疗效。方法恶性血液病患者20例,其中急性白血病3例,浆细胞白血病1例,非霍奇金淋巴瘤8例,霍奇金淋巴瘤3例,多发性骨髓瘤5例。动员方案为米托蒽醌＋长春新碱＋激素＋依托波苷方案化疗（MOEP方案）＋粒细胞集落刺激因子。经3-6d采集,获得单个核细胞（MNC）中位数为（7.23±2.27）×108/kg,CD34＋细胞（4.37±2.72）×106/kg。结果所有患者移植后均重建造血。WBC〉2.0×109/L,PLT〉20×109/L,分别为（12.04±1.76）d,（16.55±2.31）d。4例在移植6个月内死于复发,其余16例均无病存活6-55个月。结论 APBSCT对恶性血液病是一种安全有效的治疗方法。

Treatment of malignant hemopathy with autologous peripheral blood stem cell transplantation:Clinical analysis of 20 cases

Objective To observe the therapeutic effect of autologous peripheral blood stem cell transplantation（APBSCT） on malignant hemopathy.Methods Of the 20 patients with malignant hemopathy treated with APBSCT,3 were diagnosed as acute leukemia,1 as plasma cell leukemia,8 as non-Hodgkin′s lymphoma,3 as Hodgkin′s lymphoma,and 5 as multiple myeloma.All patients treated with APBSCT in combination with MOEP plus G-CSF for PBSC mobilization.The median number of mononuclear cells（MNC） and CD34＋ cells was（7.23±2.27）×108/kg and（4.37±2.72）×106/kg,respectively after PBSC was mobilized for 3-6 days.Results The hematopoietic function of patients was good after APBSCT.The mean time for the WBC and platelets to increase to 2.0×109/L and 20×109/L was 12.04±1.76 days and 16.55±2.31 days,respectively.Four patients died of relapse 6 months after APBSCT.The disease-free survival time of the remaining 16 patients was 6-55months.Conclusion APBSCT is a safe and effective procedure for malignant hemopathy.